A Review of the Properties of Spiradoline: A Potent and Selective k‐Opioid Receptor Agonist
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The selective k‐opioid receptor agonist spiradoline mesylate (U62,066E), an arylacetamide, was synthesized with the intention of creating an analgesic that, while still retaining its analgesic properties, would be devoid of the, mainly μ receptor mediated, side effects such as physical dependence and respiratory depression associated with morphine. Spiradoline is highly selective for the k receptor with Ki of 8.6 nM in guinea pig. Examination of the enantiomers of spiradoline, showed the (–)enantiomer to be responsible for the k agonist properties. Spiradoline easily penetrates the blood brain barrier, and does not seem to have any significant active metabolites. In preclinical studies, spiradoline has a short duration of action with a peak at around 30 min after administration. The analgesic properties of spiradoline are well documented in mice and rats. Antitussive properties have also been reported in rats. Furthermore, spiradoline was reported to display effects suggestive of neuroprotective properties in animal models of ischemia. In humans, spiradoline is a potent diuretic. It also produces significant sedation presumably due to its antihistamine properties. Preclinical studies have shown that spiradoline reduces blood pressure and heart rate, and has possible antiarrhythmic properties. Clinical studies did not confirm these findings. k Receptors inhibit dopaminergic neurotransmission. Spiradoline, given systematically to rats, produces a significant and long lasting decrease in dopamine release, and in loco‐motor activity. It has also antipsycho tic‐like effect in animal behavioral tests. At low doses spiradoline was reported to decrease tics in patients with Tourette's syndrome. Although spiradoline had promising effects in animal tests of analgesia, and a reasonably good safety profile in preliminary studies, it did not replace morphine as an analgesic. The available clinical data suggest that spiradoline produces disturbing adverse effects such as diuresis, sedation, and dysphoria at doses lower than those needed for analgesic effects. Thus, future development of spiradoline‐like analgesic compounds should preferably focus on reduction of unwanted effects on the central nervous system. Spiradoline, which currently is commercially available for preclinical research, might prove useful in some psychiatric conditions and possibly as a neuroprotective agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
Di Chiara, G., & Imperato, A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24578-5 · Cited by 916
Species differences in the concentrations and distributions of opioid binding sites
Robson, L. E., Gillan, M. G. C., & Kosterlitz, H. W. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90239-0 · Cited by 101
Cited by
Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis
Carlezon, W. A., & Thomas, M. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.075 · Cited by 561
Dynorphin, stress, and depression
Knoll, A. T., & Carlezon, W. A. (2010) · Brain Research · doi:10.1016/j.brainres.2009.09.074 · Cited by 465
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169
“to m-receptor agonism, k-receptor agonism has been associated with adverse effects on mood in humans (Pfeiffer et al, 1986; Wadenberg, 2003) and rodents (Carlezon et al, 2009; Mague et al, 2003).”
BackgroundDoes the kappa opioid receptor system contribute to pain aversion?
Cahill, C. M., Taylor, A. M. W., Cook, C., Ong, E., Morón, J. A., & Evans, C. J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00253 · Cited by 105
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats
Nemeth, C. L., Paine, T. A., Rittiner, J. E., Béguin, C., Carroll, F. I., Roth, B. L., Cohen, B. M., & Carlezon, W. A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1834-7 · Cited by 104
Metadata
- Authors
- Wadenberg, M. G.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2003-06
- Volume
- 9
- Issue
- 2
- Pages
- 187-198
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2145182954
- Cited by
- 123
- References
- 3
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of the Properties of Spiradoline: A Potent and Selective k‐Opioid Receptor Agonist. https://app.cochat.ai/papers/10.1111/j.1527-3458.2003.tb00248.x
- The paper
- Wadenberg, M. G. (2003). A Review of the Properties of Spiradoline: A Potent and Selective k‐Opioid Receptor Agonist. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2003.tb00248.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.